LEADS
The Longitudinal Early-Onset Alzheimer’s Disease Study (LEADS) is funded by the National Institute on Aging (NIA) to address several major gaps in Alzheimer’s disease and related dementias research. LEADS is an observational study that will enroll and follow up to 850 cognitively impaired individuals and 100 cognitively unimpaired individuals ages 40-64 at 18 sites across the United States. The study seeks to advance the understanding of all manifestations of younger-onset AD through clinical and cognitive assessments, neuroimaging, blood and cerebrospinal fluid biomarkers, genetic testing, and finally autopsy. LEADS researchers are working to uncover novel insights into the mechanisms, heterogeneity, and heritability of AD.
Study Participants
LEADS is an observational study that will enroll and follow up to 850 cognitively impaired individuals and 100 cognitively unimpaired individuals ages 40-64 at 18 sites across the United States.
Available Data
As the largest, most comprehensive study of individuals with early-onset Alzheimer’s disease, LEADS is seeking to partner with researchers across the country. Data and biospecimens from LEADS are shared with researchers with the goal of furthering translation of the research into knowledge, treatments, and procedures to improve human health. LEADS uses a standard set of protocols and procedures to collect several types of data. Data is shared for free with authorized investigators through the LEADS Data Sharing Committee.
The Data Request Application can be found here.
Available Biospecimens
Genomic DNA, Plasma, Serum, RNA, PBMC and CSF are available from NCRAD.